14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today ATRA ranks #16231 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Atara Biotherapeutics Stock Forecast NASDAQ:ATRA

$15.18 (-5.30%)

Volume: 901k

Closed: Oct 25, 2021

Hollow Logo Score: -5.211

Atara Biotherapeutics Stock Forecast

$15.18 (-5.30%)

Volume: 901k

Closed: Oct 25, 2021

Score Hollow Logo -5.211

Atara Biotherapeutics Company Profile

611 Gateway Boulevard

South San Francisco CA 94080

650-278-8930

www.atarabio.com

Industry: Biotechnology

Sector: Healthcare

Atara Biotherapeutics

Description

Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for patients with severe and life-threatening diseases. Its products under development include EBV-CTL, which is Phase II clinical trials for the treatment of malignancies associated with Epstein Barr Virus (EBV), including EBV-associated post-transplant lymphoproliferative disorders; CMV-CTL that is in Phase II clinical trials for the treatment of cytomegalovirus (CMV); WT1-CTL, which is in Phase I clinical trial for the treatment of cancers expressing the antigen Wilms Tumor 1. The company is also developing STM 434, that is in Phase I clinical trial for the treatment of ovarian cancer and other solid tumors; and a pipeline of product candidates that are in preclinical development. It has research collaboration with Memorial Sloan Kettering Cancer Center to discover and develop T-cell product candidates. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in South San Francisco, California.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE